KRISGO
4 minutes ago
Their only weapon is PR, as they lack substance and won’t survive long-term. In our case, dilution is the issue, but I believe the momentum will pick up once we get the approval. Immunotherapy approval in the GBM space is huge, and once that happens, everything else will follow—partners, funding, an